AGC Biologics Invests in New Viral Vector Suspension Capabilities at U.S. Cell & Gene Hub
New technology and capacity help CDMO’s advanced-therapies campus meet growing market demand SEATTLE, May 17, 2022 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in […]
Continue Reading